tbuckley/cabot-search huggingface dataset:
TCT-557 New Generation Drug-eluting Stents vs. Bare Metal Stents for Primary Angioplasty in Patients &gt; 75 Years With ST Elevated Myocardial Infarction: The ESTROFA-MI+75 study
Authors: Jose M. De la Torre Hernandez, Salvatore Brugaletta, Joan A. Gomez Hospital, Jose A. Baz, Armando Pérez de Prado, Ramon Lopez Palop, Belen Cid, Alejandro Diego-Nieto, Federico Gimeno, Jose Antonio Fernandez Diaz, Juan Sanchis, Fernando Alfonso, Roberto Blanco, Javier Botas Rodriguez, Javier Navarro Cuartero, Jose Moreu, Francisco Bosa, Jose Miguel Vegas, Jaime Elizaga, Jose A. Linares, Felipe Hernandez, Antonio L. Arrebola-Moreno, Marta Monteagudo, Neus Salvatella, Alfredo Gómez Jaume, Josepa Mauri
Journal: Journal of the American College of Cardiology (2015)
Study on the Efficacy and Safety of IGIV3I Grifols (Human Intravenous Immunoglobulin) in Patients Diagnosed with Chronic Immune Thrombocytopenic Purpura.
Authors: Antonio Julia, Lidia Kovaleva, Ignacio Alberca, Fernando Hernandez, Svetlana Loria, Virgilio Sandoval, Antonio Vidaller, Jorge Sierra
Journal: Blood (2006)
High-Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Transplantation (AHCT) for Non-Hodgkin’s Lymphoma (NHL) in Patients over 65 Years of Age.
Authors: Chitra Hosing, Rima M. Saliba, Grace-Julia Okoroji, Uday Popat, Daniel Couriel, Partow Kebriaei, Tanveer Ali, Marcos De Lima, Muzaffar Qazilbash, Paolo Anderlini, Sergio Giralt, Richard E. Champlin, Issa Khouri
Journal: Blood (2006)
A gene expression signature that distinguishes malignant from benign thyroid nodules.
Authors: Song Tian, John DiCarlo, Jiaye Yu, George J Quellhorst, Raymond K Blanchard, Thomas J Fahey, Michael J Crowley, Nadejda Slepushkina, Vikram Devgan, Xiao Zeng
Journal: Journal of Clinical Oncology (2012)

e21011 Background: Thyroid nodules can be detected in as high as 67% of the population. Distinguishing thyroid cancers from benign lesions is crucial for determining an appropriate treatment plan. For years a gene expression signature for discriminating malignant from benign thyroid nodules has been sought by clinicians. In this study, multivariate bioinformatics tools were used to generate a qPCR based gene expression signature for determining malignancy in thyroid nodules. Methods: Multiple mathematical models, such as Random Forest, Support Vector Machine (SVM), and Nearest Shrunken Centroid (NSC), were used to analyze published microarray data sets and select 366 putative classifier (biomarker) mRNA targets. The selected 366 genes were further evaluated for their expression pattern by real-time PCR using a panel of 49 pathology assessed thyroid nodule samples (fresh frozen, 23 malignant and 26 benign). Results: Using the qPCR data set, Random Forest was compared with SVM and NSC classifier methods and was found to be more successful in finding genes with better discriminative powers. A Random Forest method identified a panel of 7 genes together with 5 reference genes as a gene expression signature for thyroid malignancy, which led to the development of a companion classifying algorithm to provide a probability score to assess malignancy of thyroid nodules. In our limited sample set, this signature was shown to distinguish malignant and benign thyroid nodules with 92% accuracy and 100% specificity. Conclusions: Our results suggest that a combination of multiple bioinformatics analysis tools is the proper approach for biomarker candidate selection from high-throughput gene expression data. As demonstrated here, panel of 12 genes and a companion classification algorithm has the potential to successfully discriminate malignant thyroid nodule with high accuracy and specificity. This panel of twelve genes is for molecular biology applications only.
Uniting Big Health Data for a National Learning Health System in the United States
Authors: Sage R. Myers, Brendan G. Carr, Charles C. Branas
Journal: JAMA Pediatrics (2016)

This Viewpoint discusses the potential to create a national health data system with detailed patient- and hospital-level data sets that could help identify gaps in care; scientifically test regional, state, and federal policies in an iterative manner; and improve health care and outcomes nationwide.
Hyperglycemia in stem cell transplant recipients: A modifiable risk factor for infection
Authors: V. D. Cataldo, P. Shah, X. Wang, R. E. Champlin, N. T. Ueno
Journal: Journal of Clinical Oncology (2008)

9605 Background: Hyperglycemia in critically ill patients is associated with increased mortality, organ dysfunction, and number of blood-borne infections. The catabolic effects of chemotherapy and the use of steroids in stem cell transplant recipients increase the likelihood of hyperglycemia. However, the effects of hyperglycemia in this patient population are unknown. Thus, we hypothesized that hyperglycemia increases the incidence of documented infections during the peri-transplant period. Methods: We conducted a retrospective review of the incidence of hyperglycemia with respect to documented infections in all patients who were admitted to our institution for an initial stem cell transplant over a 3 month period. Exclusion criteria included outpatient and subsequent transplants. Glucose data consisted of serum levels and bedside testing levels from admission to discharge. Valid infections included blood-borne infections, line-associated infections, sputum/bronchial infections (excluding normal flora or yeast), and urinary tract infections occurring during admission. Results: Patient characteristics: 59 males and 51 females, median age of 49 (range: 18–72). Disease types: AML 35, Multiple Myeloma 21, Non-Hodgkin’s Lymphoma 21, Hodgkin’s Lymphoma 11, ALL 7, CLL 6, CML 5, and others, totaling 110 patients. Forty patients (36.4%) met American Diabetes Association criteria for diabetes mellitus (DM) during admission. Forty-three patients (39.1%) developed a valid infection during admission. A majority of patients meeting DM criteria (52.5%) developed a valid infection during admission versus 31.4% of those not meeting DM criteria (p=0.02). Twenty-three patients developed acute graft-versus-host disease (GVHD) (23.6%) for which 22 of these patients received steroid therapy. The incidence of infections of those with GVHD was significantly higher than in those without GVHD (57.7% vs 34.5%, p=0.035). Conclusions: With respect to risk of infection, hyperglycemia poses significant risk to patients undergoing stem cell transplantation. Steroid therapy in the setting of GVHD is associated with a significant increase in the risk of infection. Hyperglycemia demands aggressive management to reduce the incidence of infections during the peri-transplant period. No significant financial relationships to disclose.
TCT-403 Procedural, In-Hospital And One-Year Outcome Of Provisional Versus Planned Rotational Atherectomy In Complex Calcified Coronary Lesions
Authors: Abdelhakim Allali, Dmitriy S. Sulimov, John Jose Erungaren, Volker Geist, Guido Kassner, Gert Richardt, Mohamed Abdel-Wahab
Journal: Journal of the American College of Cardiology (2015)
Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with single agent cetuximab
Authors: W. Zhang, M. Gordon, A. M. Schultheis, F. Nagashima, M. Azuma, D. Yang, S. Iqbal, H. Lenz
Journal: Journal of Clinical Oncology (2006)

3028 Background: Cetuximab is a chimeric immunoglobulin G1 anti-EGFR monoclonal antibody with efficacy in metastatic colorectal cancer patients refractory to irinotican chemotherapy. Recent studies show that Antibody-dependent cellular cytotoxicity (ADCC) mediated through Fc receptors plays an important role in the antitumor effect of IgG1 antibody. There are three classes of FcγRs involved in the regulation of ADCC. FcγRIIa(CD32) and FcγRIIIa(CD16) activates and FcγRIIb inhibits activation. Clinical studies show FcγRIIIa 158 V/F polymorphism was associated with tumor response and progression-free survival in the follicular lymphoma patients treated with rituximab as first line treatment. Also, a H/R polymorphism at position 131 of FcγRIIa has been found to affects its affinity to human IgG and independently predict response to Rituximab. Since Cetuximab and Rituximab belong to the same chimeric IgG1 monoclonal antibody, we test hypothesis whether these two FcγR polymorphisms associated with clinical outcome in colorectal cancer patients treated with single agent Cetuximab. Methods: we tested both FcγRIIIa 158 V/F and FcγRIIa 131 H/R gene polymorphisms using PCR-RFLP method in genomic DNA extracted from peripheral blood from 39 EGFR-expressing metastatic colorectal cancer patients enrolled in a phase II single agent Cetuximab treatment clinical trial (IMCL-0144). Results: We found patients with FcγRIIa 131 HH or HR genotype show better time to progression and overall survival compare to patients with R/R genotype (p=0.037, p=0.22, respectively, log-rank test). Also, there is trend significance in tumor response when we compare patients with RR genotype and patients with HH or HR genotype (p=0.08, fisher’s exact test). FcγRIIIa 158 V/F also show trend significance in tumor response (p=0.067, fisher’s exact test). Conclusions: These data suggest Two Immunoglobulin G Fragment C Receptor polymorphismsFcγRIIIa158V/F andFcγRIIa 131 H/R may be potential molecular markers for clinical outcome of refractory metastatic colorectal caner patients treated with single agent EGFR inhibitor Cetuximab. Prospective studies are needed to confirm these preliminary findings. [Table: see text]
Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers.
Authors: Petros Giannikopoulos, John A. St. John, Joel S Parker, Oscar Westesson, Nicholas J. Hahner, Niki Karachaliou, Carlota Costa, Aleah F. Caulin, Maria D. Lozano, Jose Luis Perez-Gracia, Alessandra Curioni Fontecedro, Eloisa Jantus-Lewintre, Alain Vergnenegre, Radj Gervais, Rodolfo Bordoni, Rolf A. Stahel, Andres Felipe Cardona Zorrilla, Jonathan S. Weissman, William Reilly Polkinghorn, Trever Grant Bivona
Journal: Journal of Clinical Oncology (2014)

8083 Background: Patients with EGFR-mutant NSCLC often respond initially to EGFR kinase inhibitor therapy but ultimately relapse. The spectrum of clinical resistance mechanisms and mechanistically appropriate therapeutic strategies to enhance EGFR inhibitor treatment responses remains incompletely defined. Methods: We used whole exome and transcriptome deep sequencing analysis of tumors obtained from 16 EGFR-mutant NSCLC patients both prior to EGFR inhibitor therapy and at clinical resistance to identify the spectrum and biological basis of molecular alterations that could drive therapy resistance and be targeted to enhance clinical responses. Results: Tumors with acquired EGFR TKI resistance harbored individual and concurrent established resistance-conferring alterations, including EGFRT790M and upregulation of several receptor kinases, and other molecular alterations not previously associated with this resistance, including activating KRAS mutations. Pathway analysis of the transcriptome data revealed upregulation of ERBB2 and FGFR signaling broadly in the therapy-resistant tumors and that the EGFRT790M positive resistant tumors exhibited therapy-induced upregulation of biological pathways underlying cell cycle progression and genome maintenance. The evolution of EGFRT790M-positive resistance was also associated with increased genetic divergence and genomic instability. Genomic amplification and increased levels of the NF-kB inhibitor NFKBIA correlated with improved EGFR TKI response. Conclusions: This genome-scale characterization of the molecular landscape of EGFR inhibitor resistance uncovered biological programs and molecular events underlying the evolution of resistance, establishes the utility of whole exome and transcriptome deep sequencing in repeat biopsy specimens from NSCLC patients, and provides rationale for serial, comprehensive tumor molecular profiling in individual cancer patients to enhance therapeutic precision and response. Our findings also uncovered new molecular biomarkers of therapy response and provide new insight into the biological basis and complexity underlying the evolution of resistance.
Concurrent Diffuse Pyelonephritis and Prostatitis
Authors: Robert Lucaj, Dwight M. Achong
Journal: Clinical Nuclear Medicine (2016)

A 45-year-old man underwent FDG PET/CT for initial imaging evaluation of recurrent Escherichia coli urinary tract infections, which demonstrated no significant FDG uptake in either kidney and subtle FDG uptake in the right prostate lobe. Subsequent 67Ga SPECT/CT demonstrated abnormal intense gallium uptake throughout the right kidney and entire prostate gland, clearly discordant with PET/CT findings and consistent with unexpected concurrent pyelonephritis and prostatitis. Although FDG has effectively replaced 67Ga in everyday clinical practice, the current case serves as a reminder that there is still a role for 67Ga in the evaluation of genitourinary infections.
Case 2-1972
Authors: Richard C. Cabot, Benjamin Castleman, Betty U. McNeely, Homayoun Kazemi, Gerald Nash
Journal: New England Journal of Medicine (1972)

Presentation of Case First admission. A 19-year-old woman was admitted to the hospital because of dyspnea.At the age of eight years she noticed that her fingers and toes turned white on exposure to the cold, and for several years thereafter she experienced morning stiffness of the fingers. During the three or four years before admission ulcerations developed at times in the fingertips; the ulcers were slow to heal, and there was occasional oozing of chalky material from the elbow. She also experienced exertional fatigue, which increased in severity and was accompanied by exertional dyspnea. During the two years before . . .
TCT-782 Clinical impact of repeat infrapopliteal interventions for critical limb ischemia
Authors: Makoto Utsunomiya, Osamu Iida, Yasutaka Yamauchi, Masatsugu Nakano, Yoshimitsu Soga, Daizo Kawasaki, Junichi Tazaki, Terutoshi Yamaoka, Kenji Suzuki, Masahiko Fujihara, Nobuhiro Suematsu, Yoshiaki Shintani, Yusuke Miyashita, Taketsugu Tsuchiya, Mitsuyoshi Takahara, Masato Nakamura
Journal: Journal of the American College of Cardiology (2015)
TCT-343 Post-procedural geometrical parameters and their impact on adverse cardiovascular events: insights from the ABSORB II trial
Authors: Pannipa Suwannasom, Felipe N. Albuquerque, Yuki Ishibashi, Yohei Sotomi, Carlos M. Campos, Yoon-Kyung Cho, Dariusz Dudek, Angel Cequier, Didier Carrié, Andres Iñiguez Romo, Marcello Dominici, Rene J. van der Schaaf, Michael Haude, Bernard Chevalier, Hector Manuel Garcia Garcia, Robbert J. de Winter, Joanna J. Wykrzykowska, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2015)
TCT-218 Balancing The Risk Between Myocardial Infarction and Clinically Significant Bleeding With Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation
Authors: Usman Baber, Gennaro Giustino, Samantha Sartori, Roxana Mehran, Annapoorna Kini, Samin K. Sharma, George Dangas
Journal: Journal of the American College of Cardiology (2015)
A Comparison of Dual Attention, Eye Movements, and Exposure Only during Eye Movement Desensitization and Reprocessing for Posttraumatic Stress Disorder: Results from a Randomized Clinical Trial
Authors: Martin Sack, Stefanie Zehl, Alexander Otti, Claas Lahmann, Peter Henningsen, Johannes Kruse, Markus Stingl
Journal: Psychotherapy and Psychosomatics (2016)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Currently, there is controversy on the possible benefits of dual-attention tasks during eye movement desensitization and reprocessing (EMDR) for patients with posttraumatic stress disorder (PTSD). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A total of 139 consecutive patients (including 85 females) suffering from PTSD were allocated randomly among 3 different treatment conditions: exposure with eyes moving while fixating on the therapist's moving hand (EM), exposure with eyes fixating on the therapist's nonmoving hand (EF), and exposure without explicit visual focus of attention as control condition (EC). Except for the variation in stimulation, treatment strictly followed the standard EMDR manual. Symptom changes from pre- to posttreatment were measured with the Clinician-Administered PTSD Scale (CAPS) by an investigator blinded to treatment allocation. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; In total, 116 patients completed the treatment, with an average of 4.6 sessions applied. Intention-to-treat analysis revealed a significant improvement in PTSD symptoms with a high overall effect size (Cohen's d = 1.96, 95% CI: 1.67-2.24) and a high remission rate of PTSD diagnosis (79.8%). In comparison to the control condition, EM and EF were associated with significantly larger pre-post symptom decrease (&amp;#x0394;CAPS: EM = 35.8, EF = 40.5, EC = 31.0) and significantly larger effect sizes (EM: d = 2.06, 95% CI: 1.55-2.57, EF: d = 2.58, 95% CI: 2.01-3.11, EC: d = 1.44, 95% CI: 0.97-1.91). No significant differences in symptom decrease and effect size were found between EM and EF. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; Exposure in combination with an explicit external focus of attention leads to larger PTSD symptom reduction than exposure alone. Eye movements have no advantage compared to visually fixating on a nonmoving hand.
TCT-81 Six Versus Twelve Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: A Randomized Substudy of the I-LOVE-IT 2 Trial
Authors: Yaling Han, Kai Xu, Quanmin Jing, Jing Li, Yi Li
Journal: Journal of the American College of Cardiology (2015)
GW27-e0379 Apelin attenuates aortic adventitial fibrosis in spontaneously hypertensive rats through modulating miR-1 and beta-catenin signaling
Authors: Jiuchang Zhong, Ran Xu, Zhenzhou Zhang, Yingle Xu, Laijiang Chen, Gavin Y. Oudit, Qing Chang, Bei Song, Pingjin Gao, Jiuchang Zhong
Journal: Journal of the American College of Cardiology (2016)
Margaret Anne Evelyn Baker
Authors: Tim Baker
Journal: BMJ (2016)

Margaret Anne Evelyn Baker (nee Stuart) was described at her funeral as a “sociable, determined lady, who had a precise mind and great sense of fun, who was always busy, and who had an amazing life story.”

She was born to a third generation Singapore family, the only child of a lawyer and nurse. At the age of 6, she was sent to boarding school in Sydney and lived with her cousins; she did not …
A prospective multi-center ovarian cancer screening study in women at increased risk
Authors: S. J. Skates, C. W. Drescher, C. Isaacs, J. M. Schildkraut, D. K. Armstrong, S. S. Buys, W. R. Brewster, M. B. Daly, D. M. Finkelstein, K. H. Lu
Journal: Journal of Clinical Oncology (2007)

5510 Background: No proven ovarian cancer (OC) screening strategy exists for women who are at increased risk for the disease. A risk of ovarian cancer algorithm (ROCA) using serial CA125 values has previously shown greater positive predictive value (PPV) and sensitivity than a single CA125 in screening women at general population risk. We hypothesized that using ROCA would yield a reasonable PPV for ovarian cancer screening in a cohort at increased risk. Methods: Between 7/2001 and 9/2006, 25 sites (14 Cancer Genetics Network, 3 ovarian SPOREs, 1 EDRN, 7 others) prospectively enrolled patients. Inclusion criteria included: among self, 1° or 2° relatives in same lineage either (i) BRCA1/2 mutation, or (ii) two of OC or early onset (age = 50) breast cancer (BC), or (iii) Ashkenazi ethnicity and 1 of OC or BC. A previous diagnosis of OC excluded subjects. Subjects underwent CA125 every 3 months and the risk of having ovarian cancer based on the CA125 profile was recalculated after each test. ROCA referred subjects with risk &gt; 1% to ultrasound (US), and risk &gt; 10% additionally to a gynecologic oncologist. Objectives included PPV for study indicated surgery, sensitivity, and compliance. Sample size was chosen to observe 8 OC endpoints with a power of 80% to rule out PPV = 10% if the true PPV = 20%. Results: 2,343 high risk women enrolled, with 6,284 women years of screening and 19,549 CA125s obtained. There were 628 (10%/yr) referrals to US with 414 US performed. 38 women underwent study indicated surgeries. 9 OCs were identified during screening, 3 were prevalent (1 early, 2 late stage), and 6 were incident (5/6 = 83% early, 1 late). 3 of the 6 incident cases were found on prophylatic oophorectomy in early stage. ROCA detected 2 in early stage of remaining 3 incident cases, and 3 of 3 prevalent cases. The PPV was 5/38 = 13% (95% CI 4.4%, 28%) and sensitivity was 5/6 = 83%, CI (36%, 99%). There was high compliance with CA125 testing throughout study, with 84%, 85%, 85%, 82% subjects returning within 1 month of schedule for first 4 tests. Conclusions: Frequent CA125 testing using ROCA results in an acceptable PPV and high compliance in a cohort of women at increased risk for OC. A definitive screening study (= 30 incident cases) using ROCA with serial CA125 and possibly additional markers is required to define sensitivity for early stage OC. [Table: see text]
P-145 Prospective Phase II Trial of Combination Treatment of Whole Hepatic Irradiation and Hyperthermia in Chemorefractory Numerous Hepatic Metastases of Gastrointestinal Malignancy
Authors: J.I. Yu, H.C. Park, D.H. Choi, D. Oh, J.M. Noh, J.H. Jang, W.K. Kang, H.Y. Lim, Y.S. Park, J.O. Park, S.H. Park, J. Lee, S.T. Kim
Journal: Annals of Oncology (2015)
Impact of platinum/pemetrexed versus other platinum-based regimens on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.
Authors: Xiaoyu Zhai, Ziping Wang, Lu Yang, Yixiang Zhu
Journal: Journal of Clinical Oncology (2016)

e20011 Background: Adjuvant chemotherapy improves the survival for completely resected non-small cell lung cancer (NSCLC) patients. Platinum/pemetrexed is known to be less toxicity ,better chemotherapy compliance and longer survival in advanced non-squamous NSCLC, but the survival outcome compared with other regimens in adjuvant setting is still unknown. This report described the survival in adjuvant chemotherapy for NSCLC with platinum/pemetrexed versus other platinum-based doublets. Methods: 390 completely radical surgery non-squamous NSCLC patients who received adjuvant chemotherapy with platinum/pemetrexed regimen (Group A, n = 144) and non-pemetrexed platinum-based regimens (Group B, n = 246) were analyzed retrospectively. Primary end point was disease-free survival (DFS). Propensity score matching(PSM) allowed best matched pairs for platinum/pemetrexed versus other platinum-based doublets and a survival analysis of the match data was carried out. Results: PSM created treatment groups for platinum/pemetrexed versus non-pemetrexed regimen (86 pairs), docetaxel (8 pairs), paclitaxel (64 pairs), gemcitabine (46 pairs), and vinorelbine (22 pairs)-contained doublets, respectively. Although DFS was not significantly different between Group A and B (P = 0.197), in 86 PSM pairs, DFS was considerably better in patients who received platinum/pemetrexed regimen (P = 0.019). But in sub-group analysis, the above result was not observed in PSM groups of platinum/pemetrexed versus docetaxel (P = 0.845), paclitaxel (P = 0.108), gemcitabine (P = 0.282), and vinorelbine (P = 0.575)-contained doublets, respectively. Conclusions: Current evidence appears to favor adjuvant chemotherapy with platinum/pemetrexed arm in terms of the disease-free survival in completely resected non-squamous NSCLC, adjuvant chemotherapy with platinum/pemetrexed provides better efficacy than other platinum-based regimens. Larger sample of cases should be warranted in future.
HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.
Authors: Paul Coppo, Virginia Lepage, Marc Busson, Agnes Veyradier, Karine Clabault, Alain Wynckel, Pascale Poullin, Sandrine Malot, Elie Azoulay, Lionel Galicier, Marc Buffet, Dominique Bordessoule, Jean-Paul Mira, Eric Rondeau, Dominique Charron, Pascale Loiseau
Journal: Blood (2009)